Merck & Co., Inc. $MRK Stock Acquired by Park Avenue Securities LLC

Park Avenue Securities LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 6.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 114,282 shares of the company’s stock after purchasing an additional 7,416 shares during the period. Park Avenue Securities LLC’s holdings in Merck & Co., Inc. were worth $16,606,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Gratus Wealth Advisors LLC raised its holdings in Merck & Co., Inc. by 1.0% during the 3rd quarter. Gratus Wealth Advisors LLC now owns 9,335 shares of the company’s stock worth $1,357,000 after purchasing an additional 89 shares during the last quarter. Aegis Wealth Management Inc. lifted its position in Merck & Co., Inc. by 1.4% during the 3rd quarter. Aegis Wealth Management Inc. now owns 8,718 shares of the company’s stock valued at $1,267,000 after purchasing an additional 119 shares during the period. Patton Albertson Miller Group LLC lifted its position in Merck & Co., Inc. by 17.3% during the 3rd quarter. Patton Albertson Miller Group LLC now owns 46,821 shares of the company’s stock valued at $6,804,000 after purchasing an additional 6,898 shares during the period. Westover Capital Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 8.9% in the 3rd quarter. Westover Capital Advisors LLC now owns 12,763 shares of the company’s stock valued at $1,855,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Blume Capital Management Inc. boosted its stake in shares of Merck & Co., Inc. by 32.4% in the 3rd quarter. Blume Capital Management Inc. now owns 1,854 shares of the company’s stock valued at $269,000 after purchasing an additional 454 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna’s personalized melanoma vaccine reduced the risk of recurrence or death by 42% when added to Keytruda in a Phase 3 trial. The result supports Merck’s strategy of using new therapies to help extend Keytruda’s commercial franchise, although the benefit was below some investor expectations. Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
• Positive Sentiment: Merck reported promising Phase 3 results for sacituzumab tirumotecan, which reduced the risk of death by 32% and disease progression or death by 41% versus chemotherapy in certain advanced or recurrent endometrial cancer patients. The data could expand Merck’s oncology pipeline, with an FDA decision expected by June 2027. Sacituzumab Tirumotecan Phase 3 Results
• Positive Sentiment: Barclays raised its MRK price target from $150 to $180 and maintained an “overweight” rating, citing potential from Merck’s oncology pipeline and vaccine partnership. Barclays Stock Recommendations
• Neutral Sentiment: Investors are focused on Merck’s Q3 results, particularly Keytruda sales, Winrevair growth, full-year guidance and management’s plans to commercialize the melanoma vaccine. Keytruda remains a major growth engine, but the company’s shares sit below their 50-day moving average ahead of the report. Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?
• Negative Sentiment: Despite strong Keytruda and newer-drug sales, analysts are lowering estimates amid Gardasil weakness and concerns about Keytruda’s patent expiry in December 2028. The personalized vaccine may help retain patients, but its potential revenue would be modest relative to Keytruda’s franchise.
• Negative Sentiment: The melanoma vaccine’s 42% recurrence-risk reduction was below the roughly 49% result from its earlier trial, tempering enthusiasm. Merck’s shares were relatively resilient compared with Moderna because the program’s potential earnings contribution is less material to Merck.
• Negative Sentiment: New U.S. restrictions on certain China biotechnology collaborations could limit Merck’s access to potential drug candidates and research partnerships, adding longer-term pipeline and sourcing uncertainty. What Do New China Biotech Curbs Mean For Merck Stock?

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Sanford C. Bernstein lifted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Barclays increased their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the company an “overweight” rating in a report on Monday. BMO Capital Markets increased their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, August 20th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $153.12.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last ninety days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $141.83 on Wednesday. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The stock’s 50-day moving average price is $146.90 and its two-hundred day moving average price is $126.16.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 2.64 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.